Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial / Grau-Pujol, Berta; Camprubí-Ferrer, Daniel; Marti-Soler, Helena; Fernández-Pardos, Marc; Carreras-Abad, Clara; Andrés, Maria Velasco-de; Ferrer, Elisabet; Muelas-Fernandez, Magdalena; Jullien, Sophie; Barilaro, Giuseppe; Ajanovic, Sara; Vera, Isabel; Moreno, Laura; Gonzalez-Redondo, Eva; Cortes-Serra, Núria; Roldán, Montserrat; Arcos, Ana Artes-de; Mur, Isabel; Domingo, Pere; Garcia, Felipe; Guinovart, Caterina; Muñoz, Jose. - In: TRIALS. - ISSN 1745-6215. - 22:1(2021). [10.1186/s13063-021-05758-9]
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial
Barilaro, GiuseppeInvestigation
;
2021
Abstract
Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period.| File | Dimensione | Formato | |
|---|---|---|---|
|
Grau-pujol_Hydroxychloroquine_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
800.23 kB
Formato
Adobe PDF
|
800.23 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
